Article Sidebar

Submitted
31 October 2016
Accepted
31 October 2016
Published
2 November 2016
Download
PDF
Statistic
Read Counter : 969 Download : 3704

Main Article Content

Abstract

Cyclosporine and methylprednisolone combination are second line therapy for moderate to severe systemic lupus erythemathosus. Some study suggest that the combination were effective to decrease of systemic lupus erythematosus disease activity. But record from the study, cyclosporine cause nephrotoxicity side effect. Therefore, this study should be considered to monitore therapy effect on disease activity and renal side effect. The aim of this study is to analyze the effect of cyclosporine and methylprednisolone combination therapy on disease activity in systemic lupus erythematosus (SLE) assessed by MEX-SLEDAI and renal side effect assessed by creatinine, ureum and proteinuria. A cohort, observational prospective study was conducted to determine the effect of cyclosporine and methylprednisolone combination therapy on disease activity of SLE and renal side effect of this combination. Patients who met criteria were given cyclosporine and methylprednisolone combination that normally renal function tests. MEX-SLEDAI score, creatinine, ureum and proteinuria were measured for fourth times (one time in one mounth), before study, 1st mounth, 2nd mounth, and 3rd mounth. The study comprised 9 patients SLE were given cyclosporine and methylprednisolone combination that normally renal function tests. All patients were female and had productive age. At 3rd mounth, there was increase patients who had MEX-SLEDAI score <2 (55,6%) and one patient (11,1%) had increase of creatinine, ureum and proteinuria. In conclusion, cyclosporine and methylprednisolone combination therapy showed the effectiveness and safety in 88,9% patients and renal dysfunction in 11,1% patients.

Keywords

cyclosporine methylprednisolone SLE MEX-SLEDAI creatinine ureum proteinuria.

Article Details

License

Copyright (c) 2016 Desantika Wuryana, Bagus PP Suryana, Yulistiani Yulistiani

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Wuryana, D., Suryana, B. P., & Yulistiani, Y. (2016). EFFECTIVITY AND RENAL SAFETY OF CYCLOSPORINE AND METHYLPREDNISOLONE COMBINATION THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). Folia Medica Indonesiana, 51(3), 156–161. https://doi.org/10.20473/fmi.v51i3.2824
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Bertsias, G et al. 2012, ‘Systemic Lupus Erythematosus : Pathogenesis and Clinical Feature', in Carvera, R et al. EULAR Textbook on Rheumatic Diseases, EULAR, pp. 476 – 505.
  2. Griffiths, B., et al., 2010. Original Article: The BILAG Multi-Centre Open Randomized Controlled Trial Comparing Ciclosporin Vs Azathioprine in Patients With Severe SLE, Rheumatology, 49: 723-732.
  3. Khanna, S et al. 2004, ‘The Relationship Between Disease Activity and Quality of Life in Systemic Lupus Erythematosus', Rheumatology, vol. 4, pp. 1536 – 1540.
  4. Lacy, Charles F. et all., 2009. Drug Information Handbook 18th Edition. New York: Lexi-Comp Inc.
  5. Mok, C & Lau, CS 2003, ‘Pathogenesis of Systemic Lupus Erythematosus', Journal of Clinical Pathology, vol. 56, no.7, pp. 481 – 490.
  6. Naesens, M., et al., 2009. Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of The American Society of Nephrology 4: 481-508.
  7. Ogawa, H., et al., 2010, Efficacy and Safety of Cyclosporine A in Patients With Refractory Systemic Lupus Erythematosus in A Daily Clinical Practice, Lupus, 19: 162-169.
  8. Palestine, A. G., et al., 1984. Side Effects of Systemic Cyclosporine in Patients Not Undergoing Trans-plantation. The American Journal of Medicine, Vol 77: 652-656.
  9. Perhimpunan Reumatologi Indonesia, 2011, Rekomendasi Perhimpunan Reumatologi Indonesia Untuk Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik, Perhimpunan Reumatologi Indonesia. p: 1-36
  10. Parker, BJ & Bruce, IN 2007, ‘High Dose Methyl-prednisolone Therapy for the Treatment of Severe Systemic Lupus Erythematosus', Lupus, No.16, pp. 387 – 393.